| Drug General Information |
| Drug ID |
D0T8RL
|
| Former ID |
DNC009849
|
| Drug Name |
2-(2-(2-fluorophenoxy)phenyl)acetic acid
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H11FO3
|
| Canonical SMILES |
C1=CC=C(C(=C1)CC(=O)O)OC2=CC=CC=C2F
|
| InChI |
1S/C14H11FO3/c15-11-6-2-4-8-13(11)18-12-7-3-1-5-10(12)9-14(16)17/h1-8H,9H2,(H,16,17)
|
| InChIKey |
LAVKHAMQQVBXLL-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Interleukin-8 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Cytokine-cytokine receptor interaction
|
|
Chemokine signaling pathway
|
|
NF-kappa B signaling pathway
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Legionellosis
|
|
Chagas disease (American trypanosomiasis)
|
|
Malaria
|
|
Amoebiasis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Influenza A
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Bladder cancer
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
IL-7 Signaling Pathway
|
|
IL5 Signaling Pathway
|
|
IL1 Signaling Pathway
|
|
TSH Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
TNFalpha Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interleukin signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Glucocorticoid receptor regulatory network
|
|
ATF-2 transcription factor network
|
|
IL8-mediated signaling events
|
|
AP-1 transcription factor network
|
|
IL8- and CXCR2-mediated signaling events
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
Syndecan-2-mediated signaling events
|
|
Syndecan-3-mediated signaling events
|
|
IL8- and CXCR1-mediated signaling events
|
|
Reactome
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
Peptide ligand-binding receptors
|
|
Chemokine receptors bind chemokines
|
|
ATF4 activates genes
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
SIDS Susceptibility Pathways
|
|
Senescence and Autophagy in Cancer
|
|
IL-3 Signaling Pathway
|
|
Bladder Cancer
|
|
Activation of Genes by ATF4
|
|
EBV LMP1 signaling
|
|
Spinal Cord Injury
|
|
Corticotropin-releasing hormone
|
|
Allograft Rejection
|
|
TSLP Signaling Pathway
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. Epub 2009 Jun 13.Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. |
|---|
